B Cell Maturation Antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17),is encoded by TNFRSF17 gene in human. It is a transmembrane signaling protein preferentially expressed on plasma cells. It is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF). Its ligands including BAFF and A Proliferation Inducing Ligand (APRIL). BCMA is involved in JNK and NF-kB activation pathways that induce B-cell development and autoimmune responses. BCMA has been implicated in autoimmune disorders as well as B-lymphocyte malignancies, leukemia, lymphomas, and multiple myeloma.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | Inquiry & Datasheet |
CAR-T-1-L335-2 | Anti-BCMA scFv h(CD28) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD28 | Lentiviral | T cell | |
CAR-T-1-L335-G | Anti-BCMA scFv h(FcεRIγ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-FcεRIγ | Lentiviral | T cell | |
CAR-T-1-L335-Z | Anti-BCMA scFv h(CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L335-2G | Anti-BCMA scFv h(CD28-FcεRIγ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD28-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-L335-2Z | Anti-BCMA scFv h(CD28-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD28-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L335-4G | Anti-BCMA scFv h(CD4-FcεRIγ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD4-FcεRIγ | Lentiviral | T cell | |
CAR-T-2-L335-4Z | Anti-BCMA scFv h(CD4-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD4-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L335-8Z | Anti-BCMA scFv h(CD8-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD8-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L335-BZ | Anti-BCMA scFv h(41BB-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-2-L335-CZ | Anti-BCMA scFv h(b2c-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-b2c-CD3ζ | Lentiviral | T cell | |
CAR-T-3-L335-2BZ | Anti-BCMA scFv h(CD28-41BB-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD28-41BB-CD3ζ | Lentiviral | T cell | |
CAR-T-3-L335-2XZ | Anti-BCMA scFv h(CD28-OX40-CD3ζ) CART, pCDCAR1 | Human | MM0108-3D44 | Rat | scFv-CD28-OX40-CD3ζ | Lentiviral | T cell | |
CAR-LC002 | Anti-BCMA (J6M0)h(41BB-CD3ζ) CAR, pCDCAR1 | Human | J6M0 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC135 | Anti-BCMA (P5A2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | P5A2 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC136 | Anti-BCMA (A02_Rd4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | A02_Rd4 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC137 | Anti-BCMA (P5C1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | P5C1 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC138 | Anti-BCMA (C01_Rd4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | C01_Rd4 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC139 | Anti-BCMA (COMBO_Rd4) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | COMBO_Rd4 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC140 | Anti-BCMA (L3PY/H2DY) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | L3PY/H2DY | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC141 | Anti-BCMA (P6AP-V1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | P6AP-V1 | Human | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC260 | Anti-BCMA (C12A3.2) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | C12A3.2 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC261 | Anti-BCMA (BC50) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BC50 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC262 | Anti-BCMA (BC30) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BC30 | Mouse | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-LC285 | Anti-TNFRSF17 h(CD28-OX40-CD3ζ) Ligand-based CAR, pCDCAR1 | Human | Human | dAPRIL-CD28-OX40-CD3ζ | Retroviral | T cell | ||
CAR-LC286 | Anti-TNFRSF17 h(CD8STK-CD28-OX40-CD3ζ) Ligand-based CAR, pCDCAR1 | Human | Human | dAPRIL-CD8STK-CD28-OX40-CD3ζ | Retroviral | T cell | ||
CAR-MZ014 | Anti-BCMA (C13F12.1) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | C13F12.1 | Humanized | scFv-41BB-CD3ζ | Lentiviral | T cell | |
CAR-MZ122 | Anti-BCMA (11D5-3) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 11D5-3 | Mouse | scFv-CD28-CD3ζ | Retroviral | T cell | |
CAR-YF134 | Anti-BCMA (7A12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7A12 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-YF135 | Anti-BCMA (23F10) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 23F10 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-YF136 | Anti-BCMA (23F10) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 23F10 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-YF137 | Anti-BCMA (25C2) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 25C2 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-YF138 | Anti-BCMA (25C2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 25C2 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-YF139 | Anti-BCMA (25D2) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 25D2 | Humanized | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-YF140 | Anti-BCMA (25D2) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 25D2 | Humanized | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |
CAR-YF220 | Anti-BCMA (BCMA-50) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | BCMA-50 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP007 | Anti-BCMA (CT053) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | CT053 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP008 | Anti-BCMA (bb21217) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | bb21217 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP009 | Anti-BCMA (Descartes-08) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | Descartes-08 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP010 | Anti-BCMA (BCMA-CART) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | BCMA-CART | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell | |
CAR-ZP012 | Anti-BCMA (J22.9) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | J22.9 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T cell |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE